176 related articles for article (PubMed ID: 17165773)
1. Design, synthesis, and computational studies of inhibitors of Bcl-XL.
Park CM; Oie T; Petros AM; Zhang H; Nimmer PM; Henry RF; Elmore SW
J Am Chem Soc; 2006 Dec; 128(50):16206-12. PubMed ID: 17165773
[TBL] [Abstract][Full Text] [Related]
2. Fragment-based deconstruction of Bcl-xL inhibitors.
Barelier S; Pons J; Marcillat O; Lancelin JM; Krimm I
J Med Chem; 2010 Mar; 53(6):2577-88. PubMed ID: 20192224
[TBL] [Abstract][Full Text] [Related]
3. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.
Petros AM; Dinges J; Augeri DJ; Baumeister SA; Betebenner DA; Bures MG; Elmore SW; Hajduk PJ; Joseph MK; Landis SK; Nettesheim DG; Rosenberg SH; Shen W; Thomas S; Wang X; Zanze I; Zhang H; Fesik SW
J Med Chem; 2006 Jan; 49(2):656-63. PubMed ID: 16420051
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship studies of phenanthridine-based Bcl-XL inhibitors.
Bernardo PH; Wan KF; Sivaraman T; Xu J; Moore FK; Hung AW; Mok HY; Yu VC; Chai CL
J Med Chem; 2008 Nov; 51(21):6699-710. PubMed ID: 18925736
[TBL] [Abstract][Full Text] [Related]
6. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.
Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK
J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577
[TBL] [Abstract][Full Text] [Related]
7. Identification of lead compounds as antagonists of protein Bcl-xL with a diversity-oriented multidisciplinary approach.
Di Micco S; Vitale R; Pellecchia M; Rega MF; Riva R; Basso A; Bifulco G
J Med Chem; 2009 Dec; 52(23):7856-67. PubMed ID: 19852471
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and interaction study of quinazoline-2(1H)-thione derivatives as novel potential Bcl-xL inhibitors.
Feng Y; Ding X; Chen T; Chen L; Liu F; Jia X; Luo X; Shen X; Chen K; Jiang H; Wang H; Liu H; Liu D
J Med Chem; 2010 May; 53(9):3465-79. PubMed ID: 20405848
[TBL] [Abstract][Full Text] [Related]
9. A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.
Levoin N; Vo DD; Gautier F; Barillé-Nion S; Juin P; Tasseau O; Grée R
Bioorg Med Chem; 2015 Apr; 23(8):1747-57. PubMed ID: 25797160
[TBL] [Abstract][Full Text] [Related]
10. Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening.
Mukherjee P; Desai P; Zhou YD; Avery M
J Chem Inf Model; 2010 May; 50(5):906-23. PubMed ID: 20392095
[TBL] [Abstract][Full Text] [Related]
11. Photocontrollable peptide-based switches target the anti-apoptotic protein Bcl-xL.
Kneissl S; Loveridge EJ; Williams C; Crump MP; Allemann RK
Chembiochem; 2008 Dec; 9(18):3046-54. PubMed ID: 19012295
[TBL] [Abstract][Full Text] [Related]
12. Beta-hairpin peptidomimetics: design, structures and biological activities.
Robinson JA
Acc Chem Res; 2008 Oct; 41(10):1278-88. PubMed ID: 18412373
[TBL] [Abstract][Full Text] [Related]
13. Heat-induced dimerization of BCL-xL through alpha-helix swapping.
Denisov AY; Sprules T; Fraser J; Kozlov G; Gehring K
Biochemistry; 2007 Jan; 46(3):734-40. PubMed ID: 17223694
[TBL] [Abstract][Full Text] [Related]
14. The N-terminal domain of tumor suppressor p53 is involved in the molecular interaction with the anti-apoptotic protein Bcl-Xl.
Xu H; Tai J; Ye H; Kang CB; Yoon HS
Biochem Biophys Res Commun; 2006 Mar; 341(4):938-44. PubMed ID: 16455050
[TBL] [Abstract][Full Text] [Related]
15. Isosteric exchange of the acylsulfonamide moiety in Abbott's Bcl-XL protein interaction antagonist.
Dömling A; Antuch W; Beck B; Schauer-Vukasinović V
Bioorg Med Chem Lett; 2008 Jul; 18(14):4115-7. PubMed ID: 18583128
[TBL] [Abstract][Full Text] [Related]
16. De-novo designed library of benzoylureas as inhibitors of BCL-XL: synthesis, structural and biochemical characterization.
Brady RM; Vom A; Roy MJ; Toovey N; Smith BJ; Moss RM; Hatzis E; Huang DC; Parisot JP; Yang H; Street IP; Colman PM; Czabotar PE; Baell JB; Lessene G
J Med Chem; 2014 Feb; 57(4):1323-43. PubMed ID: 24456288
[TBL] [Abstract][Full Text] [Related]
17. Crystallographic and computational studies on 4-phenyl-N-(beta-D-glucopyranosyl)-1H-1,2,3-triazole-1-acetamide, an inhibitor of glycogen phosphorylase: comparison with alpha-D-glucose, N-acetyl-beta-D-glucopyranosylamine and N-benzoyl-N'-beta-D-glucopyranosyl urea binding.
Alexacou KM; Hayes JM; Tiraidis C; Zographos SE; Leonidas DD; Chrysina ED; Archontis G; Oikonomakos NG; Paul JV; Varghese B; Loganathan D
Proteins; 2008 May; 71(3):1307-23. PubMed ID: 18041758
[TBL] [Abstract][Full Text] [Related]
18. Glycogen phosphorylase inhibitors: a free energy perturbation analysis of glucopyranose spirohydantoin analogues.
Archontis G; Watson KA; Xie Q; Andreou G; Chrysina ED; Zographos SE; Oikonomakos NG; Karplus M
Proteins; 2005 Dec; 61(4):984-98. PubMed ID: 16245298
[TBL] [Abstract][Full Text] [Related]
19. Structure and function of benzoylurea-derived alpha-helix mimetics targeting the Bcl-x(L)/Bak binding interface.
Rodriguez JM; Ross NT; Katt WP; Dhar D; Lee GI; Hamilton AD
ChemMedChem; 2009 Apr; 4(4):649-56. PubMed ID: 19330783
[TBL] [Abstract][Full Text] [Related]
20. Are AM1 ligand-protein binding enthalpies good enough for use in the rational design of new drugs?
Villar R; Gil MJ; García JI; Martínez-Merino V
J Comput Chem; 2005 Oct; 26(13):1347-58. PubMed ID: 16021597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
